Related Experiment Video

Updated: Jun 12, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

[Effects of PTK787 on cell proliferation and expression of fak mRNA in K562]

Xiao-Hua Di1, Ri-Ling Chen, Xiao-Li Liu

  • 1Department of Paediatrics, Affiliated Hospital, Guangdong Medical College, Zhanjiang 524001, Guangdong Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|June 22, 2010
PubMed

Insights

Tyrosine kinase inhibitor PTK787 effectively inhibits chronic myeloid leukemia (CML) cell proliferation by blocking cell cycle progression and reducing fak mRNA expression. This study explores PTK787

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome.
  • Targeted therapies, including tyrosine kinase inhibitors (TKIs), have revolutionized CML treatment.
  • Understanding the mechanisms of TKIs is crucial for optimizing therapeutic strategies against leukemia.

Purpose:

  • To investigate the effects of PTK787 on K562 cell proliferation, cell cycle, and fak mRNA expression.
  • To elucidate the anti-leukemic mechanism of PTK787 in human chronic myeloid leukemia (CML) cell line K562.
  • To explore the potential of PTK787 as a therapeutic agent against acute myeloid leukemia.

Summary:

  • PTK787 demonstrated a dose- and time-dependent inhibition of K562 cell proliferation.
  • Treatment with PTK787 led to an accumulation of cells in the G1 phase and a decrease in the S phase.
  • PTK787 significantly reduced the expression of fak mRNA in K562 cells.

Impact:

  • PTK787 exhibits anti-leukemic activity by interfering with cell cycle progression and fak mRNA expression.
  • These findings suggest PTK787 as a potential therapeutic candidate for CML and possibly other myeloid leukemias.
  • The study provides insights into the molecular mechanisms underlying PTK787's efficacy in leukemia treatment.

More Related Videos

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration10:43

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration

Published on: May 19, 2016

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...